Dementia - Pipeline Review, H1 2014
2014 Jun 30
116 Pages (PDF)
Dementia - Pipeline Review, H1 2014 Summary Global Markets Directs, Dementia - Pipeline Review, H1 2014, provides an overview of the Dementias therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Dementia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dementia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Dementia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Dementia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Dementia Overview 10 Therapeutics Development 11 Pipeline Products for Dementia - Overview 11 Pipeline Products for Dementia - Comparative Analysis 12 Dementia - Therapeutics under Development by Companies 13 Dementia - Therapeutics under Investigation by Universities/Institutes 16 Dementia - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Unknown Stage Products 21 Dementia - Products under Development by Companies 22 Dementia - Products under Investigation by Universities/Institutes 23 Dementia - Companies Involved in Therapeutics Development 24 Bristol-Myers Squibb Company 24 Sylentis S.A. 25 FORUM Pharmaceuticals Inc. 26 Ildong Pharmaceutical Co., Ltd. 27 SK Chemicals Co., Ltd. 28 WhanIn Pharmaceutical Co., Ltd. 29 Hyundai Pharmaceutical Co., Ltd. 30 Summit Corporation plc 31 Oryzon Genomics S.A. 32 Intellect Neurosciences, Inc. 33 Intra-Cellular Therapies, Inc. 34 Tautatis Incorporated 35 Pacific Northwest Biotechnology, LLC 36 Otsuka Holdings Co., Ltd. 37 Chase Pharmaceuticals Corporation 38 Echo Pharmaceuticals B.V. 39 Chronos Therapeutics Limited 40 Alector LLC 41 ImStar Therapeutics Inc. 42 Dementia - Therapeutics Assessment 43 Assessment by Monotherapy Products 43 Assessment by Target 44 Assessment by Mechanism of Action 48 Assessment by Route of Administration 52 Assessment by Molecule Type 54 Drug Profiles 56 brexpiprazole - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 FRM-0334 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 dronabinol - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 ITI-007 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 ARC-100 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 choline alfoscerate SR - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 TTT-3002 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Small Molecules To Inhibit LSD-1 And MAO-B For Neurodegenerative Diseases - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 OG-45 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Seglin O-linked N-acetylglucosaminidase Inhibitors - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Gugulipid - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 RDC-5 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Peptide BACE Inhibitor - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 TauC3 Monoclonal Antibody - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Drugs For Dementia - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Drugs to Agonize c-MET for Dementia - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Drugs to Inhibit Matrix Metalloproteinase for Dementia And Cognitive Impairment - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 KR-12 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 OG-635 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Hexanoic-Tyrosine-Histidine-(6) Aminohexanoic Amide - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Small Molecules for Age Related Cataracts, Macular Degeneration and Neurodegenerative Disorders - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Small Molecule to Inhibit Cathepsin B for Neurology disorders - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 IPN-007 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 NNC-269100 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimers Disease - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Antisense Oligonucleotide to Inhibit microRNA for Neurology - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 IRL-752 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 SID-111 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Small Molecule to Inhibit G Family for Dementia - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 WIB-1001C - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 T-01OX2 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 Small Molecules to Activate Progranulin for Frontotemporal Dementia - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 Antibodies for Dementia and Alzheimers Disease - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 CPC-252 - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 Dementia - Recent Pipeline Updates 98 Dementia - Dormant Projects 107 Dementia - Discontinued Products 108 Dementia - Product Development Milestones 109 Featured News & Press Releases 109 Mar 03, 2014: Intra-Cellular Therapies Announces Initiation of Phase I/II Clinical Trial for ITI-007 in Healthy Geriatric Subjects and Patients with Dementia, Including Alzheimer's Disease 109 Jan 09, 2014: Adamas Pharmaceuticals Earns $40 Million in Milestone Payments from Forest Laboratories for MDX-8704 110 Oct 31, 2013: Eisai Submits Application to Expand Indication of Anti-alzheimer's Agent Aricept As Treatment for Dementia with Lewy Bodies in Japan 110 Oct 26, 2012: New Research Demonstrates Potential Of IRX4204 For Reduction Of Dementia In Animal Models Of Alzheimer's And Parkinson's Disease 111 Jul 16, 2012: Resverlogix Establishes Clinical And Scientific Advisory Board To Support Clinical Development Of RVX-208 111 Nov 08, 2011: NeuroSearch Publishes MermaiHD Study In The Lancet Neurology 112 Jun 30, 2011: NeuroSearch Provides Update On Clinical Development Program For Huntexil 112 Feb 23, 2011: Intellectual Property High Court of Japan Rules to Maintain Aricept Patent Term Extension in Relation to Severe Alzheimer's Dementia 112 Jul 24, 2010: Eisai Announces U.S. FDA Approval for New Higher Dose Aricept 23mg Tablet for the Treatment of Moderate-to-severe Alzheimers Disease 113 Jul 22, 2010: Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KGaA Settle NAMENDA Patent Litigation 114 Appendix 115 Methodology 115 Coverage 115 Secondary Research 115 Primary Research 115 Expert Panel Validation 115 Contact Us 116 Disclaimer 116
Bristol-Myers Squibb Company Sylentis S.A. FORUM Pharmaceuticals Inc. Ildong Pharmaceutical Co., Ltd. SK Chemicals Co., Ltd. WhanIn Pharmaceutical Co., Ltd. Hyundai Pharmaceutical Co., Ltd. Summit Corporation plc Oryzon Genomics S.A. Intellect Neurosciences, Inc. Intra-Cellular Therapies, Inc. Tautatis Incorporated Pacific Northwest Biotechnology, LLC Otsuka Holdings Co., Ltd. Chase Pharmaceuticals Corporation Echo Pharmaceuticals B.V. Chronos Therapeutics Limited Alector LLC ImStar Therapeutics Inc.